GlassScriptPhysician profile
Michael R Simpson
NPI 1780652719
$1,687.46
in general payments reported to CMS, 2019-2025
21 companies · $701 in 2025
The $701 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2022: $17.17 · 2023: $110 · 2024: $638 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $311.31 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $198.81 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $151.29 | 2024-2025 | |
| Lilly USA, LLC | $140.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $130.87 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $120.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $118.53 | 2019-2025 | |
| Amgen INC. | $111.09 | 2019-2025 | Repatha, Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $76.74 | 2024 | Hetlioz, Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $73.35 | 2024-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.84 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $40.47 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $21.98 | 2019 | |
| Allergan, INC. | $19.91 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.62 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $17.59 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.51 | 2019 | |
| Shire North American Group INC | $16.01 | 2019 | |
| Abbott Laboratories | $15.69 | 2025 | Eterna |
| Merck Sharp & Dohme LLC | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.